肿瘤科指南

订阅

MedSci主页 / 所有栏目 / 肿瘤科指南

卡瑞利珠单抗致反应性皮肤毛细血管增生症临床诊治专家共识

2020-09-30 中国临床肿瘤学会抗肿瘤药物安全管理专家委员会 临床肿瘤学杂志.2020.25(9):840-848.

卡瑞利珠单抗

卡瑞利珠单抗( SHR-1210，Camrelizumab，Cam)是一种具有自主知识产权、独特结构和功能的国产ICIs，经国家药品监督管理局( NMPA) 批准上市，陆续获得了治疗多种肿瘤的适应证，

中文标题：

卡瑞利珠单抗致反应性皮肤毛细血管增生症临床诊治专家共识

发布机构：

中国临床肿瘤学会抗肿瘤药物安全管理专家委员会

发布日期：

2020-09-30

简要介绍：

卡瑞利珠单抗( SHR-1210，Camrelizumab，Cam)是一种具有自主知识产权、独特结构和功能的国产ICIs，经国家药品监督管理局( NMPA) 批准上市，陆续获得了治疗多种肿瘤的适应证，正在临床上广泛使用。为了更好指导临床上合理使用Cam 治疗恶性肿瘤，在NMPA 药审中心( CDE) 建议和指导下，CSCO 抗肿瘤药物安全管理专家委员会和免疫治疗专家委员会组织多学科专家，根据Cam 临床前研究和临床试验的数据、上市后真实世界的观察以及实践用药经验，参考国内、外有关重要文献，认真讨论，多次修改，形成了本专家共识，作为临床医师用药时的重要参考，以保障患者治疗的有效性、安全性和耐受性。

相关资料下载：
[AttachmentFileName(sort=1, fileName=卡瑞利珠单抗致反应性皮肤毛细血管增生症临床诊治专家共识_秦叔逵.pdf)] GetToolGuiderByIdResponse(projectId=1, id=5f1771c0019950c5, title=卡瑞利珠单抗致反应性皮肤毛细血管增生症临床诊治专家共识, enTitle=, guiderFrom=临床肿瘤学杂志.2020.25(9):840-848., authorId=0, author=, summary=卡瑞利珠单抗( SHR-1210，Camrelizumab，Cam)是一种具有自主知识产权、独特结构和功能的国产ICIs，经国家药品监督管理局( NMPA) 批准上市，陆续获得了治疗多种肿瘤的适应证，, cover=https://img.medsci.cn/20201023/1603466664951_2020535.jpg, journalId=0, articlesId=null, associationId=964, associationName=中国临床肿瘤学会抗肿瘤药物安全管理专家委员会, associationIntro=null, copyright=0, guiderPublishedTime=Wed Sep 30 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>卡瑞利珠单抗( SHR-1210，Camrelizumab，Cam)是一种具有自主知识产权、独特结构和功能的国产ICIs，经国家药品监督管理局( NMPA) 批准上市，陆续获得了治疗多种肿瘤的适应证，正在临床上广泛使用。为了更好指导临床上合理使用Cam 治疗恶性肿瘤，在NMPA 药审中心( CDE) 建议和指导下，CSCO 抗肿瘤药物安全管理专家委员会和免疫治疗专家委员会组织多学科专家，根据Cam 临床前研究和临床试验的数据、上市后真实世界的观察以及实践用药经验，参考国内、外有关重要文献，认真讨论，多次修改，形成了本专家共识，作为临床医师用药时的重要参考，以保障患者治疗的有效性、安全性和耐受性。</p> </div> </div> </div>, tagList=[TagDto(tagId=90913, tagName=卡瑞利珠单抗)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=90913, guiderKeyword=卡瑞利珠单抗, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=8859, appHits=161, showAppHits=0, pcHits=2068, showPcHits=8698, likes=2, shares=14, comments=5, approvalStatus=1, publishedTime=Sat Oct 24 00:09:27 CST 2020, publishedTimeString=2020-09-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Fri Oct 23 23:24:29 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Fri Jan 05 12:28:00 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=卡瑞利珠单抗致反应性皮肤毛细血管增生症临床诊治专家共识_秦叔逵.pdf)])
卡瑞利珠单抗致反应性皮肤毛细血管增生症临床诊治专家共识_秦叔逵.pdf
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1228171, encodeId=560612281e104, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220718/40f20a20ac39449bb9b54f0a56b3bd59/badab63a8f8940b1aa22f908b6cb9dc4.jpg, createdBy=5b9f6414712, createdName=ms5000000275821148, createdTime=Thu Jun 23 09:54:47 CST 2022, time=2022-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053808, encodeId=3d0e1053808a2, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd1c2561472, createdName=125638e2m96暂无昵称, createdTime=Wed Sep 22 15:29:05 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011418, encodeId=39411011418ae, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33975125063, createdName=14643a05m23暂无昵称, createdTime=Wed Aug 25 17:01:28 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946518, encodeId=58cd9465187f, content=太棒了，学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2b85466921, createdName=ms4000001441347419, createdTime=Mon Mar 08 19:47:27 CST 2021, time=2021-03-08, status=1, ipAttribution=)]
    2022-06-23 ms5000000275821148

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1228171, encodeId=560612281e104, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220718/40f20a20ac39449bb9b54f0a56b3bd59/badab63a8f8940b1aa22f908b6cb9dc4.jpg, createdBy=5b9f6414712, createdName=ms5000000275821148, createdTime=Thu Jun 23 09:54:47 CST 2022, time=2022-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053808, encodeId=3d0e1053808a2, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd1c2561472, createdName=125638e2m96暂无昵称, createdTime=Wed Sep 22 15:29:05 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011418, encodeId=39411011418ae, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33975125063, createdName=14643a05m23暂无昵称, createdTime=Wed Aug 25 17:01:28 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946518, encodeId=58cd9465187f, content=太棒了，学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2b85466921, createdName=ms4000001441347419, createdTime=Mon Mar 08 19:47:27 CST 2021, time=2021-03-08, status=1, ipAttribution=)]
    2021-09-22 125638e2m96暂无昵称

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1228171, encodeId=560612281e104, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220718/40f20a20ac39449bb9b54f0a56b3bd59/badab63a8f8940b1aa22f908b6cb9dc4.jpg, createdBy=5b9f6414712, createdName=ms5000000275821148, createdTime=Thu Jun 23 09:54:47 CST 2022, time=2022-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053808, encodeId=3d0e1053808a2, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd1c2561472, createdName=125638e2m96暂无昵称, createdTime=Wed Sep 22 15:29:05 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011418, encodeId=39411011418ae, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33975125063, createdName=14643a05m23暂无昵称, createdTime=Wed Aug 25 17:01:28 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946518, encodeId=58cd9465187f, content=太棒了，学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2b85466921, createdName=ms4000001441347419, createdTime=Mon Mar 08 19:47:27 CST 2021, time=2021-03-08, status=1, ipAttribution=)]
    2021-08-25 14643a05m23暂无昵称

    好

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1228171, encodeId=560612281e104, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220718/40f20a20ac39449bb9b54f0a56b3bd59/badab63a8f8940b1aa22f908b6cb9dc4.jpg, createdBy=5b9f6414712, createdName=ms5000000275821148, createdTime=Thu Jun 23 09:54:47 CST 2022, time=2022-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053808, encodeId=3d0e1053808a2, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd1c2561472, createdName=125638e2m96暂无昵称, createdTime=Wed Sep 22 15:29:05 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011418, encodeId=39411011418ae, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33975125063, createdName=14643a05m23暂无昵称, createdTime=Wed Aug 25 17:01:28 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=946518, encodeId=58cd9465187f, content=太棒了，学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2b85466921, createdName=ms4000001441347419, createdTime=Mon Mar 08 19:47:27 CST 2021, time=2021-03-08, status=1, ipAttribution=)]
    2021-03-08 ms4000001441347419

    太棒了，学习了

    0